Male Reproductive System Carcinoma

subtype

Identifier: CI-CAN-00003134
Entity page: /cancer/male-reproductive-system-carcinoma ↗
Edges: 1,575

Neighbours: 15 genes22 drugs10 trials
Drawn: 47 of 47 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Male Reproductive System Carcinoma approved for …APPROVED_FORderived41 of 41show fewer
← approved for	Docetaxelsmall molecule FDA (US) · approved · 2024-10-23 · Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer	—	approved	Castration-Resistant Prostate Carcinoma	1	Regulatory	openfda	graph →
approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

CDK12 Mutation OlaparibFDA US 2017-08-1711 active / 28 trials
Curatedlevel Asensitivity· support 1civicObservedCDK12 altered in 5.7% (118 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
CHEK2 mutation OlaparibFDA US 2017-08-1711 active / 28 trials
Curatedlevel Asensitivity· support 1civicObservedCHEK2 altered in 4.2% (21 / 499 cases)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
ATM Mutation OlaparibFDA US 2017-08-1711 active / 28 trials
Curatedlevel Asensitivity· support 1civicObservedATM altered in 4.2% (86 / 2,069 cases, largest of 8 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BRCA2 Mutation OlaparibFDA US 2017-08-1711 active / 28 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BRCA2 Mutation RucaparibFDA US 2016-12-192 active / 7 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 3.6% (74 / 2,069 cases, largest of 7 cohorts)Regulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Castration-Resistant Prostate Carcinoma
BARD1 Mutation OlaparibFDA US 2017-08-1711 active / 28 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BARD1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BRCA1 Mutation OlaparibFDA US 2017-08-1711 active / 28 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinoma (2 approval records)context: Castration-Resistant Prostate Carcinoma
BRCA1 Mutation RucaparibFDA US 2016-12-192 active / 7 trials
Curatedlevel Asensitivity· support 1civicObservedcohort frequency not yet available for BRCA1 in this cancerRegulatoryapproved for Castration-Resistant Prostate Carcinomacontext: Castration-Resistant Prostate Carcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Male Reproductive System Carcinoma altered in cohorts of …ALTERED_INderived15 of 144show all (up to 200)
← altered in cohorts of	CCAR2 298 / 500 cases (60 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BIN3 297 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	C8orf58 297 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	XPO7 297 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BMP1 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PEBP4 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PIWIL2 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PPP3CC 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	RHOBTB2 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SORBS3 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TNFRSF10C 296 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DMTN 295 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	DOK2 295 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	EGR3 295 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM160B2 295 / 500 cases (59 %) · ssm · TCGA-PRAD	—	—	Prostate Adenocarcinoma	1	Observed	gdc	graph →

Male Reproductive System Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 173show all (up to 200)
→ investigated in trials for	Enzalutamidesmall molecule 109 trials (41 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	109	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 73 trials (28 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	73	Observed	clinicaltrials	graph →
→ investigated in trials for	Abiraterone Acetatesmall molecule 54 trials (26 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 52 trials (18 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Leuprolideother 39 trials (20 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Abirateronesmall molecule 35 trials (15 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Apalutamidesmall molecule 29 trials (19 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Bicalutamidesmall molecule 29 trials (9 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 28 trials (11 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Goserelinother 27 trials (13 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 27 trials (10 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabazitaxelsmall molecule 25 trials (14 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 25 trials (14 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 22 trials (12 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Lutetium (177lu) Vipivotide Tetraxetanother 19 trials (14 active) · roll-up of the cancer and its descendants	—	—	Male Reproductive System Carcinoma	19	Observed	clinicaltrials	graph →

Male Reproductive System Carcinoma studied in …STUDIED_INderived10 of 1,217show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 1,217 trials mapped (494 active)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 1,217 trials mapped (494 active)	—	—	Penile Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05081193Phase 2 · active not recruiting Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer · condition mapped ALIAS · 1,217 trials mapped (494 active)	—	—	Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06541210NA · recruiting Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men · condition mapped ONTOLOGY_EXACT · 1,217 trials mapped (494 active)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06738303Phase 2 · recruiting Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer · condition mapped CURATED_BROADER · 1,217 trials mapped (494 active)	—	—	Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07185165Phase 2 · recruiting An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer. · condition mapped ONTOLOGY_EXACT · 1,217 trials mapped (494 active)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07667400Phase 1/Phase 2 · not yet recruiting Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer · condition mapped CURATED_BROADER · 1,217 trials mapped (494 active)	—	—	Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06031805active not recruiting PRostate Olaparib Real World Evidence Study · condition mapped CURATED_BROADER · 1,217 trials mapped (494 active)	—	—	Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06472817enrolling by invitation Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men · condition mapped ONTOLOGY_EXACT · 1,217 trials mapped (494 active)	—	—	Prostate Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07594106Phase 1/Phase 2 · recruiting REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma · condition mapped CURATED_BROADER · 1,217 trials mapped (494 active)	—	—	Castration-Resistant Prostate Carcinoma	1	Observed	clinicaltrials	graph →